Principal Financial Group Inc Kinnate Biopharma Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$3.46 - $7.98 $3,086 - $7,118
892 Added 8.71%
11,135 $69,000
Q4 2022

Feb 09, 2023
BUY
$5.26 - $12.19 $53,878 - $124,862
10,243 New
10,243 $62,000

Others Institutions Holding KNTE

# of Institutions
2
Shares Held
292K
Call Options Held
0
Put Options Held
0
View Full List

About Kinnate Biopharma Inc.

KNTE Quotes by TradingView
  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email